UPDATE: Compass Point Upgrades DR Horton to Neutral on Updated Forecasts
Compass Point raised its rating on DR Horton (NYSE: DHI) from Sell to Neutral and raised its price target to $18.50.
Compass Point commented, "After a full model update we are raising estimates and, coupled with the stock's relative underperformance in the post-QE3 trade, we now feel DHI should perform in line with the rest of the space. Our price target increase reflects our increased 2013 EPS estimate to $0.93 from $0.87 as well as a consistent 5% assumed ROI. We still see downside in the shares to $18 but the stock is off 12% since the Fed announced QE3 in early September and has been the second worst performer in the homebuilding sector over that time frame."
DR Horton closed at $19.58 on Wednesday.
Latest Ratings for DHI
|Feb 2017||BTIG Research||Initiates Coverage On||Buy|
|Jan 2017||Barclays||Initiates Coverage On||Equal-Weight|
|Dec 2016||Keefe Bruyette & Woods||Upgrades||Market Perform||Outperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.